References
- Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev.58, 68–89 (2006).
- De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev.58, 52–67 (2006).
- Sun JB, Eriksson K, Li BL et al. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Clin. Immunol.112, 35–44 (2004).
- Jang MH, Kweon MN, Hiroi T et al. Induction of cytotoxic T lymphocyte responses by cholera toxin-treated bone marrow-derived dendritic cells. Vaccine21, 1613–1619 (2003).
- Wang L, Kedzierski L, Wesselingh SL et al. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun.71, 2356–2364 (2003).
- Arakawa T, Tsuboi T, Kishimoto A et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine21, 3143–3148 (2003).
- Arakawa T, Komesu A, Otsuki H et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun.73, 7375–7380 (2005).
- Yamanaka H, Ishibashi D, Yamaguchi N et al. Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin. Vaccine24, 2815–2823 (2006).
- Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience133, 413–421 (2005).
- Prusiner SB. Prions. Proc. Natl Acad. Sci. USA95, 13363–13383 (1998).
- Weissmann C, Enari M, Klohn PC et al. Molecular biology of prions. Acta Neurobiol. Exp. (Wars.)62, 153–166 (2002).
- Will RG, Alperovitch A, Poser S et al. Descriptive epidemiology of Creutzfeldt–Jakob disease in six European countries, 1993–1995. Ann. Neurol.43, 763–767 (1998).
- Duffy P, Wolf J, Collins G et al. Letter: possible person-to-person transmission of Creutzfeldt–Jakob disease. N. Engl. J. Med.290, 692–693 (1974).
- Bernoulli C, Siegfried J, Baumgartner G et al. Danger of accidental person-to-person transmission of Creutzfeldt–Jakob disease by surgery. Lancet1, 478–479 (1977).
- Koch TK, Berg BO, De Armond SJ et al. Creutzfeldt–Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N. Engl. J. Med.313, 731–733 (1985).
- Thadani V, Penar PL, Partington J et al. Creutzfeldt–Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J. Neurosurg.69, 766–769 (1988).
- Llewelyn CA, Hewitt PE, Knight RSG et al. Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet363, 417–421 (2004).
- Peden AH, Head MW, Ritchie DL et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet364, 527–529 (2004).
- Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science197, 943–960 (1977).
- Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature389, 498–501 (1997).
- Hill AF, Desbruslais M, Joiner S et al. The same prion strain causes vCJD and BSE. Nature389, 448–450 (1997).
- Collee JG, Bradley R, Liberski PP. Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: part 2. Folia. Neuropathol.44, 102–110 (2006).
- Bueler H, Aguzzi A, Sailer A et al. Mice devoid of PrP are resistant to scrapie. Cell73, 1339–1347 (1993).
- Manson JC, Clarke AR, McBride PA et al. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration3, 331–340 (1994).
- Prusiner SB, Groth D, Serban A et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl Acad. Sci. USA90, 10608–10612 (1993).
- Sakaguchi S, Katamine S, Shigematsu K et al. Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt–Jakob disease agent. J. Virol.69, 7586–7592 (1995).
- Legname G, Baskakov IV, Nguyen HO et al. Synthetic mammalian prions. Science305, 673–676 (2004).
- Castilla J, Saa P, Hetz C et al.In vitro generation of infectious scrapie prions. Cell121, 195–206 (2005).
- Heppner FL, Christ AD, Klein MA et al. Transepithelial prion transport by M cells. Nat. Med.7, 976–967 (2001).
- Mishra RS, Basu S, Gu Y et al. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J. Neurosci.24, 11280–11290 (2004).
- Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol.2, 361–367 (2001).
- Horiuchi M, Furuoka H, Kitamura N et al. Alymphoplasia mice are resistant to prion infection via oral route. Jpn. J. Vet. Res.53, 149–157 (2006).
- Kitamoto T, Muramoto T, Mohri S et al. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt–Jakob disease. J. Virol.65, 6292–6295 (1991).
- Jeffrey M, McGovern G, Goodsir CM et al. Sites of prion protein accumulation in scrapie-infected mouse spleen revealed by immuno-electron microscopy. J. Pathol.191, 323–332 (2000).
- Heggebo R, Gonzalez L, Press CM et al. Disease-associated PrP in the enteric nervous system of scrapie-affected Suffolk sheep. J. Gen. Virol.84, 1327–1338 (2003).
- Montrasio F, Frigg R, Glatzel M et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science288, 1257–1259 (2000).
- Bartz JC, Dejoia C, Tucker T et al. Extraneural prion neuroinvasion without lymphoreticular system infection. J. Virol.79, 11858–11863 (2005).
- Gabizon R, McKinley MP, Groth D et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl Acad. Sci. USA85, 6617–6621 (1988).
- Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science294, 178–182 (2001).
- White AR, Enever P, Tayebi M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature422, 80–83 (2003).
- Belay ED, Maddox RA, Williams ES et al. Chronic wasting disease and potential transmission to humans. Emerg. Infect. Dis.10, 977–984 (2004).
- Zhang RG, Scott DL, Westbrook ML et al. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol.251, 563–573 (1995).
- Zhang RG, Westbrook ML, Westbrook EM et al. The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J. Mol. Biol.251, 550–562 (1995).
- Nashar TO, Amin T, Marcello A et al. Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine11, 235–240 (1993).
- Holmgren J, Czerkinsky C, Eriksson K et al. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine21(Suppl. 2), S89–S95 (2003).
- Grdic D, Ekman L, Schon K et al. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J. Immunol.175, 5192–5202 (2005).
- Kawamura YI, Kawashima R, Shirai Y et al. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-κB translocation. Eur. J. Immunol.33, 3205–3212 (2003).
- Hagiwara Y, Iwasaki T, Asanuma H et al. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine19, 1652–1660 (2001).
- Lobet Y, Cluff CW, Cieplak W Jr. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun.59, 2870–2879 (1991).
- Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine19, 2534–2541 (2001).
- Arrington J, Braun RP, Dong L et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol.76, 4536–4546 (2002).
- Sanchez AE, Aquino G, Ostoa-Saloma P et al. Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine. Clin. Diagn. Lab. Immunol.11, 711–719 (2004).
- Bade S, Baier M, Boetel T et al. Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine24, 1242–1253 (2006).
- Areas AP, Oliveira ML, Miyaji EN et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem. Biophys. Res. Commun.321, 192–196 (2004).
- Arakawa T, Yu J, Chong DK et al. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat. Biotechnol.16, 934–938 (1998).
- Yuki Y, Byun Y, Fujita M et al. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol. Bioeng.74, 62–69 (2001).
- Sadeghi H, Bregenholt S, Wegmann D et al. Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. Immunology106, 237–245 (2002).
- George-Chandy A, Eriksson K, Lebens M et al. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect. Immun.69, 5716–5725 (2001).
- Eriksson K, Fredriksson M, Nordstrom I et al. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect. Immun.71, 1740–1747 (2003).
- Sigurdsson EM, Brown DR, Daniels M et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol.161, 13–17 (2002).
- Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA101, 14670–14676 (2004).
- Ishibashi D, Yamanaka H, Yamaguchi N et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine25(6), 985–992 (2007).
- O’Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng.18, 69–85 (2001).
- Rosset MB, Ballerini C, Gregoire S et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol.172, 5168–5174 (2004).
- Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med.10, 187–192 (2004).
- Gilch S, Wopfner F, Renner-Muller I et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem.278, 18524–18531 (2003).
- Koller MF, Grau T, Christen P. Induction of antibodies against murine full-length prion protein in wild-type mice. J. Neuroimmunol.132, 113–116 (2002).
- Nikles D, Bach P, Boller K et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J. Virol.79, 4033–4042 (2005).
- Alperovitch A, Zerr I, Pocchiari M et al. Codon 129 prion protein genotype and sporadic Creutzfeldt–Jakob disease. Lancet353, 1673–1674 (1999).
- Brandel JP, Preece M, Brown P et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet362, 128–130 (2003).
- Palmer MS, Dryden AJ, Hughes JT et al. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease. Nature352, 340–342 (1991).
- Wadsworth JD, Asante EA, Desbruslais M et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science306, 1793–1796 (2004).
- Peden AH, Ritchie DL, Ironside JW. Risks of transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Folia. Neuropathol.43, 271–278 (2005).
- Bishop MT, Hart P, Aitchison L et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol.5, 393–398 (2006).
- Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science313, 92–94 (2006).
- Behar SM, Porcelli SA. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum.38, 458–476 (1995).
- Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol.25, 61–66 (2004).
- Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med.9, 893–899 (2003).
- Gauczynski S, Nikles D, El-Gogo S et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J. Infect. Dis.194, 702–709 (2006).
- Gelinas DS, DaSilva K, Fenili D et al. Immunotherapy for Alzheimer’s disease. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14657–14662 (2004).
- Schenk D, Hagen M, Seubert P. Current progress in β-amyloid immunotherapy. Curr. Opin. Immunol.16, 599–606 (2004).
- Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science303, 1514–1516 (2004).
Website
- http://niah.naro.affrc.go.jp/disease/bse/ count.html.